ABSTRACT The biochemical basis of the mechanism of vasodilatation by nitroglycerin (NTG) has not been previously investigated in man. However, evidence from in vitro studies suggests that NTG induces activation of guanylate cyclase via a series of enzymatic reactions that are modulated by the availability of sulfhydryl groups. Cysteine appears to be particularly effective in potentiating guanylate cyclase activation by NTG. To determine whether hemodynamic responsiveness to NTG in man might be modulated by sulfhydryl availability, concentration-response curves for effects of intravenously infused NTG on mean arterial pressure (MAP) and mean pulmonary capillary wedge pressure (PCW) were obtained in 10 patients undergoing cardiac catheterization for investigation of chest pain. NTG infusion was repeated 10 min after the intravenous infusion of 100 mg/kg of the cysteine source Nacetylcysteine (NAC). NAC induced no significant hemodynamic effect, but after NAC infusion there was a significant reduction both in the NTG infusion rate associated with a 10% fall from control values in MAP (25.8 ± 8.3 to 9.3 ± 2.7 ,g/min; p < .01) and in the infusion rate inducing a 30% reduction in PCW (13.6 + 4.6 to 4.2 + 1.6 Ag/min; p < .02). In a control group of five patients who received no NAC, there was no significant change in responsiveness to NTG between infusions. It is concluded that NAC potentiates the vasodilator effects of NTG in man. This suggests that sulfhydryl availability and/ or redox state may be determinants of in vivo responsiveness to NTG.
NITROGLYCERIN (NTG) has been used as an antianginal agent for over 100 years.1 Although the efficacy of NTG in the treatment of myocardial ischemia and in some clinical settings of congestive heart failure is now well established, controversy remains concerning its mechanism of action at both the hemodynamic and cellular levels.2 Furthermore, the fundamental biochemical mechanisms of action of NTG are not well understood.
Needleman et al. 3 observed that incubation of rabbit aortic strips with the sulfhydryl alkylating agent ethacrynic acid led to a reduction in sensitivity to NTG. It was further suggested that tolerance to NTG could be induced by oxidation of sulfhydryl groups.4 These observations have led to the suggestion that the vasodilator action of NTG is closely linked to the availability of critical SH groups in vascular smooth muscle.
More recent studies using isolated tissues have tended to support this postulated role of sulfhydryl groups in modulating responses to NTG. There is now evidence consistent with the view that NTG indirectly activates guanylate cyclase and that the vasodilator effects of NTG are mediated by increased intracellular concentrations of guanosine 3', 5'-monophosphate (cyclic GMP).5. 6 Although possible modulation of this process by sulfhydryl availability may occur at several points, available data suggest that S-nitrosothiol compounds, formed by interaction of NTG with tissue sulfhydryl, activate guanylate cyclase.7' 8 Of a number of S-nitrosothiols tested, S-nitroso-cysteine was most effective in stimulating guanylate cyclase activation. 7 Thus production of S-nitrosothiols by interaction of NTG with tissue sulfhydryl groups may be an essential step in the development of NTG-induced vasodilation.
Variability in tissue sulfhydryl availability might also offer an explanation for the wide disparity in hemodynamic responsiveness to NTG at any particular plasma NTG concentration.9 However, to date no studies have been carried out to determine whether availability of sulfhydryl, or particularly cysteine, modulate responsiveness to NTG in intact animals or man. The current-ly reported series of studies were carried out to test the hypothesis that this interaction may be operative in patients with ischemic heart disease.
Methods
Patients. The study population consisted of 15 patients (12 men, three women) undergoing diagnostic cardiac catheterization and coronary arteriography for evaluation of chest pain. Presence of unstable angina pectoris, hemodynamically significant stenosis of the left main coronary artery, significant valvular heart disease, requirement for nitrate administration during the routine component of cardiac catheterization, or previous adverse reactions to NTG or N-acetylcysteine (NAC) excluded patients from entry to the study.
Informed consent was obtained in writing before cardiac catheterization. Administration of long-acting nitrate preparations or cutaneously administered NTG was halted 12 to 24 hr before catheterization; other prophylactic antianginal agents were continued in unchanged dosages and sublingually administered NTG was used as required.
Protocol. Left and right heart catheterizations were performed from the femoral approach. Cardiac index was determined by the Fick method. After completion of the diagnostic procedures, a No. 7F balloon-tipped catheter was advanced into the pulmonary artery. Baseline levels of pulmonary arterial and pulmonary capillary wedge pressures were recorded, with determination of mean pressures over a 30 sec period to minimize errors due to respiratory variation. Femoral artery pressure was recorded via the side-arm of a femoral arterial sheath."' After determination of baseline pressures, NTG infusion was initiated into a peripheral vein by means of a Model 2206 Harvard infusion pump and nonabsorbent tubing (McGaw Laboratories, Irvine, CA). The initial rate of NTG infusion was 1 ,gl min. Effects on heart rate and on femoral arterial, pulmonary arterial, and pulmonary capillary wedge pressures were determined at 5 min intervals. Infusion rates of NTG were increased every 5 min, with successive rates of 1, 2.5, 5, 10, 25, and 50 ,ug/min. Infusion was terminated after any particular rate had induced a greater than 10% fall in mean arterial pressure (MAP) or a greater than 30% fall in mean pulmonary capillary wedge pressure (PCW).
After a further 5 min, 10 patients (the NAC group) received an infusion of 100 mg/kg body weight of NAC in 200 ml of 5% dextrose via a peripheral vein over 15 min. After a further 10 min, infusion of NTG was repeated, with the same hemodynamic end points.
To assess the magnitude of spontaneous changes in respon- PRE NAC siveness to NTG during the time required for this infusion protocol, a control group of five subjects receiving only 5% dextrose (200 ml) between the first and second NTG infusions was also studied. Analysis of results. Differences in baseline parameters between patients in the NAC group and control subjects were assessed by the two-tailed unpaired Student's t test. Effects of NAC infusion (or 5% dextrose) on hemodynamic parameters between groups were assessed by the Wilcoxon rank-sum test.
Dose-response relationships for individual patients were determined after each NTG infusion by linear regression as illustrated in figures 1 and 2. The end points of NTG infusion ratesinducing a 10% reduction in MAP and a 30% reduction in PCV were obtained from the regression lines. In two patients (Nos. 3 and 4 in the control group) in whom less than 20% reductions in PCW had occurred at NTG infusion rates that reduced MAP by greater than 10%, no attempt_was made to determine the NTG infusion rate for the 30% PCW reduction end point, since this would have involved considerable extrapolation.
Statistical comparison of NTG infusion rates at hemodynamic end points within groups before and after infusion of NAC (or 5% dextrose) was performed by the Wilcoxon signed-rank test. The changes in infusion rates of NTG between the first and second NTG infusions were also compared between groups by means of the Wilcoxon rank-sum test. Comparison of infusion rates was performed by expressing the second NTG infusion rate as a percentage of the first NTG infusion rate.
Drugs. NTG was made up as a 50 ,g/ml solution in glass bottles containing 5% dextrose by dilution from ampules (Tridil; American Critical Care). Connecting tubing used for transfer of NTG from the glass syringe used in conjunction with the Harvard infusion pump was minimally absorptive of NTG (Tridilset; McGaw Laboratories). NAC for intravenous administration (Parvolex; Duncan, Flockhart and Co., London) was diluted in 5% dextrose solution.
Results
Patients. Characteristics of the patients are summarized in table 1. There was no significant difference between the NAC patients and control subjects with respect to ages or weight; previous exposure to longacting nitrates and ,3-adrenoceptor antagonists was similar in the two groups.
Findings at cardiac catheterization and baseline hemodynamic values are summarized in The initially proposed model of the NTG 'receptor"4 was based on studies in preparations of rabbit aortic strips which indicated that specific tolerance to nitrates could be induced by prolonged exposure to NTG, potentiated by alkaline pH, but reversed by the reducing agent dithiothreitol. It was suggested that NTG (and organic nitrates) reversibly oxidizes one or more sulfhydryl groups in the "receptor," leading to the formation of a disulfide form of the receptor that has a much lower affinity for NTG. The inhibitory effects of ethacrynic acid, which alkylates sulfhydryl groups, on responsiveness to NTG in vitro provided further support for this hypothesis. ' The postulated role of cyclic GMP as an intracellular mediator of NTG-induced vasodilatation5 6 makes the potential mechanism of modulation of NTG sensitivity more complex. First, a number of compounds have been shown to be potent activators of guanylate cyclase in arterial smooth muscle. These include several S-nitrosothiols, which would be formed when NO.-or nitric oxide react with a tissue sulfhydryl source.7 In these experiments, it was found that cysteine was far more effective in stimulating activation of guanylate cyclase by NTG than other sulfhydryl-containing materials such as dithiothreitol, penicillamine. and reduced glutathione. Ascorbate was totally ineffective.
This suggests that the interaction between cysteine and NTG is not purely a matter of increased availability of sulfhydryl groups or of alteration in tissue redox state. This, together with the initial responsiveness of the NAC group to NTG infusion rates of less than 100 jug/ min, suggests that the infusion system used was effective in minimizing losses of NTG.
CIRCULATION
Administration of NAC induced a clear-cut potentiation of hemodynamic responsiveness to NTG, assessed both on the basis of changes in MAP and PCW. The hypotensive effects of NTG were more markedly increased in those patients who initially had been least responsive to NTG. The most probable explanation of these findings is that NAC potentiated the vasodilator effects of NTG, presumably in both arteries and veins.
Although this cannot be stated with certainty in the absence of more extensive assessment of hemodynamic changes, the only other explanation (attenuation of the effects of NTG on cardiac output) seems unlikely.
It is possible that the greater potentiation after NAC of NTG effects in patients who were initially less responsive to the drug reflects variations among patients in initial availability of sulfhydryl groups and/or in tissue redox state. Although, the present study was not designed to evaluate this possibility, no evidence was found of effects of previous administration of longacting nitrates on either initial responsiveness or the degree of NAC-induced potentiation. Thus, while tolerance to NTG may under some circumstances be induced by long-acting nitrates,18 this did not appear to 1252 be the major determinant of responsiveness in the present series.
The results of our study suggest that, particularly in initially insensitive patients, enhanced hemodynamic responsiveness to NTG may be induced after NAC. This finding is in accordance with the results of previous in vitro studies. Whether this altered responsiveness is of clinical value in the management of ischemic heart disease and/or congestive heart failure remains to be addressed in future studies.
